Morgan Stanley’s Latigo Biotherapeutics LTGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$152K Buy
+9,112
New +$192K ﹤0.01% 6125

Other funds holding LTGO

Morgan Stanley's LTGO Position: Q3 2026 in Review

Morgan Stanley opened a new position in Latigo Biotherapeutics (LTGO) in Q3 2026: 9,112 shares worth $152K. The stake represents ﹤0.01% of the portfolio and ranks #6125 among its holdings.

58 funds tracked by Wall St. Rank hold LTGO as of Q3 2026.

  • Morgan Stanley held 9,112 shares of Latigo Biotherapeutics worth $152K as of Q3 2026.
  • Latigo Biotherapeutics was a new Morgan Stanley position in Q3 2026.
  • Latigo Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #6125 holding.
  • 58 funds tracked by Wall St. Rank held Latigo Biotherapeutics as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.